期刊文献+

新型氟喹诺酮类衍生物的设计合成及其体外抗菌活性的初探 被引量:3

The design,synthesis and in vitro antibacterial activities of novel fluoroquinolone derivatives
原文传递
导出
摘要 目的设计、合成系列新型氟喹诺酮类衍生物,并初筛其体外抗菌活性。方法通过酰胺键在洛美沙星、左氧氟沙星和加替沙星的C-7位引入乙酰基、正己酰基、苯乙酰基和三甲氧基苯乙酰基,制备了一系列氟喹诺酮类衍生物,并通过二倍稀释法进行抗菌活性初筛。结果与讨论共制备12个全新目标物,结构经^1HNMR、^13CNMR和HRMS确证。通过对金黄色葡萄球菌、大肠埃希菌和铜绿假单胞菌的体外抗菌活性初筛,发现化合物7的抗菌活性优于阳性对照。此外,在C-7位引入乙酰基的化合物7~9的抗菌活性显著优于母核相同、C-7侧链不同的结构类似物。 OBJECTIVE To design and synthesize a series of novel fluoroquinolone derivatives in order to investigate their in vitro antibacterial effects. METHODS A novel group of fluoroquinolones were synthesized by introducing ethyl, n - hexy[, phenethyl and trimethoxyphenemyl into the C - 7 position of Lomefloxacin, Levofloxacin and Gatifloxacin with an amide bond. Double - dilution method was used to measure the antibacterial activities. RESULTS and CONCLUSION 12 novel compounds were prepared and their struc- ture were confirmed by ^1 HMR, ^13 CNMR and HRMS. The compounds were evaluated for their antibacterial activities against S. aureus, E. coli and P. aeruginosa. Among them, the most potent was compound 7. In addition, it was found that compounds 7 - 9 with an acetyl group introduced into the C -7 position had significant advantages regarding antibacterial activity compared to compounds with the same quinolone moiety but different C -7 side chains.
出处 《华西药学杂志》 CAS CSCD 2015年第1期1-4,共4页 West China Journal of Pharmaceutical Sciences
基金 国家自然科学基金资助重点项目(批准号:81130026)
关键词 氟喹诺酮类衍生物 酰胺键 抗菌活性 二倍稀释法 合成 Fluoroquinolones Amide bond Antibacterial activities Double - dilution method Synthesis
  • 相关文献

参考文献8

  • 1Mantadakis E, Maraki S, Michailidis L, et al. Antimicrobial susceptibility of Gram - positive cocci isolated from patients with conjunctivitis and keratitis in Crete, Greece [ J ]. J Microbiol Immunol Infect,2013,46 ( 1 ) :41 - 47.
  • 2Livermore DM. Fourteen years in resistance [ J ]. Int J AntimicrobAgents ,2012,39 (4) :283 - 294.
  • 3Eun YJ, Foss MH, Kiekebusch D, et al. DCAP: A broad - spectrum antibiotic that targets the cytoplasmic membrane of bac- teria[J]. J Am Chem Soe,2012,134(28) :11322 -11325.
  • 4Bryskier A, Chantot JF. Classification mad structure - activity relationships of fluoroquinolones[ J]. Drugs, 1995,49 ( Suppl 2 ) : 16 - 28.
  • 5Qi QR, Pan J, Guo XQ, et al. Synthesis and antibacterial activity of new fluoroquinolones containing a cis - or trans - cyclohexane moiety[J]. Bioorg Med Chem Lett,2012,22(24) :7688 -7692.
  • 6魏臣録,潘佳,何菱,齐庆蓉.含顺反式环己烷基元喹诺酮类衍生物的合成及抗菌活性初探[J].华西药学杂志,2010,25(3):253-256. 被引量:2
  • 7Aravena - Roman M, Inglis TJJ, Henderson B, et al. Antimierobial susceptibilities of Aeromonas strains isolated from clinical and environmental sources to 26 antimierohial agents[J]. Antimierob Agents Chemother,2012,56(2) :1110 -1112.
  • 8Bigos M, Wasiela M, Kalemba D, et al. Antimierobial activity of geranium oil against clinical strains of Staphylococcus aureus [ J ]. Molecules ,2012,17 (9) : 10276 - 10291.

二级参考文献5

共引文献1

同被引文献26

  • 1Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections:A call to action for the medical community from the Infectious diseases society of america[J]. Clin Infect Dis,2008,46(2) :155 - 164.
  • 2Livermore D M. Discovery research: The scientific challenge of finding new antibiot E J ]. J Antimicrob Chemother, 2011,66 ( 9 ) : 1941 - 1944.
  • 3Wise R, Blaser M, Carrs O, et al. The urgent need for new antibacterial agents [ J ]. J Antimicrob Che- mother,2011,66 (9) : 1939 - 1940.
  • 4Bonilla H, Huband M D, Seidel J, et al. Muhicity outbreak of linezolid-resistant staphylococcus epidermi- dis associated with clonal spread of a cfr-containing strain [ J ]. Clin Infect Dis,2010,51 (7) :796 - 800.
  • 5Morales G, Pieazo J J, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus au- reus [ J ]. Clin Infect Dis,2010,50 ( 6 ) : 821 - 825.
  • 6Walsh C T , Wencewicz T A. Prospects for new anti- biotics : A molecule-centered perspective [ J ]. J Antibi- ot,2014,67( 1 ) :7 -22.
  • 7Georgopapadakou N H. Prospects for new antibacteri- als : Can we do better? [ J ]. Expert Opin Invest Drugs, 2014,23(2) :145 - 148.
  • 8Basarab G S, Brassil P, Doig P, et al. Novel DNA gyrase inhibiting spiropyrimidinetriones with a benz- isoxazole scaffold: SAR and in vivo characterization [J]. J Med Chem,2014,57(21):9078-9095.
  • 9Basarab G S, Doig P, Galullo V, et al. Discovery of novel DNA gyrase inhibiting spiropyrimidinetriones: Benzisoxazole fusion with N-linked oxazolidinone sub- stituents leading to a clinical candidate (ETX0914) [J]. J Med Chem,2015,58(15) :6264 -6282.
  • 10Basarab G S, Kern G H, McNuhy J, et al. Respon- ding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mecha- nism-of-action against bacterial type II topoisomerases [ J ]. Scientific Reports, 2015,5 : 11827.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部